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Abstract
Attenuated Edmonston measles virus (MV-Edm) is not pathogenic in standard mice. We show here that
MV-Edm inoculated via the natural respiratory route has a limited propagation in the lungs of mice with
a targeted mutation inactivating the alpha/beta interferon receptor. A high dose of MV-Edm
administered intracerebrally is lethal for about half of these mice. To study the consequences of the
availability of a high-affinity receptor for MV propagation, we generated alpha/beta interferon-defective
mice expressing human CD46 with human-like tissue specificity. Intranasal infection of these mice with
MV-Edm resulted in enhanced spread to the lungs and more prominent inflammatory response. Virus
replication was also detected in peripheral blood mononuclear cells, the spleen, and the liver. Moreover,
intracerebral inoculation of adult animals with low MV-Edm doses caused encephalitis with almost
inevitably lethal outcome. We conclude that in mice alpha/beta interferon controls MV infection and
that a high-affinity receptor facilitates, but is not strictly required for, MV spread and pathogenesis.
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Attenuated Edmonston measles virus (MV-Edm) is not pathogenic in standard mice. We show here that MV-
Edm inoculated via the natural respiratory route has a limited propagation in the lungs of mice with a targeted
mutation inactivating the alpha/beta interferon receptor. A high dose of MV-Edm administered intracerebrally
is lethal for about half of these mice. To study the consequences of the availability of a high-affinity receptor
for MV propagation, we generated alpha/beta interferon-defective mice expressing human CD46 with human-
like tissue specificity. Intranasal infection of these mice with MV-Edm resulted in enhanced spread to the lungs
and more prominent inflammatory response. Virus replication was also detected in peripheral blood mono-
nuclear cells, the spleen, and the liver. Moreover, intracerebral inoculation of adult animals with low MV-Edm
doses caused encephalitis with almost inevitably lethal outcome. We conclude that in mice alpha/beta inter-
feron controls MV infection and that a high-affinity receptor facilitates, but is not strictly required for, MV
spread and pathogenesis.
Measles remains one of the leading causes of infant death in
developing countries (40) and, in rare cases, persistent measles
virus (MV) infection induces the lethal neurodegenerative dis-
ease subacute sclerosing panencephalitis (SSPE) (10, 55). Di-
rect studies of early MV replication in humans are lacking, but
experimental studies in monkeys (32, 58) and histopathological
observations in humans (33) suggest local replication in the
respiratory mucosa a few days after infection. MV may then
spread, possibly carried in pulmonary macrophages, to drain-
ing lymph nodes and from there enter the bloodstream carried
in leukocytes, disseminating first to lymphoid tissues and then
to tissues throughout the body (40).
MV infection of adult rodents is restricted to brain-adapted
strains inoculated intracerebrally (29). These strains have sub-
stantial changes in the sequence of the receptor binding pro-
tein hemagglutinin (H) (30), alterations which may permit
more efficient MV entry into rodent cells. MV entry into
mouse cells is also more efficient with expression of CD46, the
receptor for the MV vaccine strain Edmonston (MV-Edm)
(13, 36) and probably for several wild-type strains (51, 52, 57).
However, transgenic rodents expressing CD46 are not suscep-
tible to MV infection when inoculated by the natural respira-
tory route (17, 39, 56). Nevertheless, MV-Edm intracerebral
inoculation of neonatal transgenic mice expressing one form of
CD46 in neurons resulted in disease and death (46).
To obtain mice in which MV spread can be studied, we
operated at two levels. First, knowing that alpha/beta inter-
feron controls MV infection in cultured cells (6, 28) and may
do so in patients with SSPE (15, 60), we tested whether mice
with a targeted mutation inactivating the alpha/beta interferon
receptor (Ifnartm strain) (35) are susceptible to infection with
the attenuated strain MV-Edm. Indeed we observed limited
MV spread after intranasal inoculation and 50% lethality after
high-dose intracerebral inoculation. Second, we produced the
new transgenic line CD46Ge (Ge for genomic), which, unlike
previous lines (17, 46, 56), expresses CD46 with human-like
tissue specificity (34, 42), and crossed it with Ifnartm mice to
obtain an Ifnartm-CD46Ge line. Respiratory inoculation of
these mice with MV-Edm resulted in enhanced virus spread
and more prominent lung tissue inflammation, and intracere-
bral infection was lethal at low virus doses.
MATERIALS AND METHODS
CD46 transgenic mice. A yeast strain carrying the 400-kb yeast artificial chro-
mosome (YAC) RCA1, with the CD46 gene in its center (18), was grown in
selective medium, and YAC DNA was prepared (48). Briefly, yeast cells were
embedded in agarose and lysed, the intact chromosomal DNA was separated by
pulsed-field gel electrophoresis, a gel slice with the YAC was identified and
excised, and the DNA was concentrated on a second agarose gel cast around the
slice. To compact the DNA and minimize shearing forces, buffers containing
NaCl and polyamines were used. After agarase digestion, YAC DNA was dia-
lyzed against microinjection buffer (100 mM NaCl, 10 mM Tris-HCl [pH 7.5], 0.1
mM EDTA, 30 mM spermine, 70 mM spermidine). About 2 pl of purified YAC
DNA (2 ng/ml) in microinjection buffer was injected into fertilized oocytes of
B6C3F1 hybrids, and about 30 oocytes were transferred to each pseudopregnant
foster mother. Seventeen pups were born, of which two were transgenic. One
animal (Hugo) was a rare mosaic nontransmitter, whereas TgN(hCD46Ge)
373Zbz (Teresa) transmitted its insert to about 50% of its progeny. The animals
were held, and experiments were performed, under optimal hygienic conditions.
For genotype analysis, tails from 5- to 6-week-old mice were cut (0.5 to 1 cm
in length) and DNA was prepared (26). CD46-specific PCR was based on two
primer pairs: 59-AAAGGGCAAATTACCTTAAGGGGTG and 59-AGCACTT
CGACCTAAAAATAGAGAT, amplifying 263 bp of the CD46 promoter region,
and 59-GCCAGTTCATCTTTTGACTCTATTAA and 59-CAGCATATCCCTG
CTTTAATACAAC, amplifying 249 bp of exon 14. Additionally, a primer pair
(59-CCTCGTCTTCAATAAAACATTT and 59-AGCCCTGACAGGGGGTT
AT) amplifying 369 bp of the promoter region of the MCP-like genetic element,
situated about 90 kb upstream of the CD46 gene (12), was occasionally used. The
results obtained with the three primer pairs were equivalent. Southern blots
probed with the 263-bp PCR product of the CD46 promoter and with a Prn-p
gene fragment (5), both nick translated with the Prime-it II labelling kit (Strat-
agene), allowed identification of CD46 homozygous mice (59).
To establish the Ifnartm-CD46Ge mutant line, a CD46Ge 2n male was crossed
with a homozygous Ifnartm female. The F2 progeny were screened for an inac-
tivating insertion in both alpha/beta interferon alleles (35) and for homozygosity
for CD46 (see above). The haplotype of Ifnartm mice is H-2b, and that of
Ifnartm-CD46Ge mice is H-2bk. Both the H-2b and H-2k haplotypes are highly
sensitive to MV-induced encephalitis (38).
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Viruses and infections. The MV-Edm substrain used was that adapted to grow
in HeLa cell spinner cultures by S. Udem; RNA from this substrain was also used
to reconstitute a cDNA copy of the MV genome suitable for reverse genetics
(45). The MV-P-CAT virus is a derivative of this substrain to which a transcrip-
tion unit expressing the reporter protein chloramphenicol acetyltransferase
(CAT) was added downstream of the phosphoprotein (P) gene (54). The rat
brain-adapted CAM/RBH strain and the wild-type wtF strain were kindly sup-
plied by S. Niewiesk, Wu¨rzburg, Germany. The wild-type Chicago-1 strain was
kindly supplied by D. Griffin, Baltimore, Md.
MV-Edm, MV-P-CAT, and Chicago-1 were propagated in Vero cells as de-
scribed previously (45) and used for mouse inoculation in the form of post-
nuclear supernatants (5 min at 800 3 g). The wtF strain was grown in the
Epstein-Barr virus-transformed B lymphoblastoid cell line B-LCL JP (supplied
by R. S. van Binnendijk, Utrecht, The Netherlands), and the CAM/RBH strain
was grown in rat brains; both strains were used for mouse inoculation as cell
homogenates.
For intranasal infection, 5- to 8-week-old animals were anesthetized and then
infected in both nares with 50 ml of virus in phosphate-buffered saline (PBS). For
mock infections, postnuclear supernatants of uninfected cells were used. For
intracerebral MV inoculation, 5- to 8-week-old animals were anesthetized and
injected along the skull midline with 30 ml of virus by means of a syringe with a
27-gauge needle. Infected animals, homozygous for both mutated loci, were
observed daily for clinical symptoms or death.
RNA analysis: reverse transcription-PCR, Northern blots, and in situ hybrid-
ization. For RNA extraction from organs (11), animals were sacrificed and
tissues were removed and snap frozen in liquid nitrogen. The minus-strand
primer 59-TTATAACAATGATGGAGGGTAGGC, hybridizing to the last 24
nucleotides of the nucleocapsid (N) mRNA (43), was used for reverse transcrip-
tion. PCR was based on the primer pair 59-GATGGAGGGTAGGCGGATGT
TGTTCTGGC–59-ACTCGGTATCACTGCCGAGGATGCAAGGC, amplify-
ing 474 bases of the N mRNA.
For Northern analysis 5 mg of RNA was separated by electrophoresis on a 1%
formaldehyde agarose gel and analyzed with a digoxigenin (DIG)-labelled probe
(DIG RNA labelling kit; Boehringer, Mannheim, Germany) corresponding to
851 bp of the MV N mRNA (9) or with a control DIG-labelled b-actin RNA
probe (Boehringer).
MV N-specific mRNA was detected in tissue sections with DIG-labelled N
RNA of negative polarity. After deparaffinization, 2-mm-thick sections were
processed as instructed by the manufacturer (Boehringer) with the following
modifications. Prehybridization was at 37°C for 2 h without proteinase K pre-
treatment. One hundred microliters of DIG-labelled N RNA probe (30 pg/ml in
hybridization buffer with Denhardt’s solution) was added to each section, and the
sections were incubated at 68°C overnight in a humid chamber. Immunological
detection was done with the DIG-nucleic acid detection kit (Boehringer). The
sections were developed for 6 h at room temperature in the dark.
Protein analysis: Western blot, CAT assay, and histopathology. Mouse organs
were snap frozen in liquid nitrogen. Human tissues were collected 9 to 15 h
postmortem. The tissues were homogenized with an Ultra-Turrax T25 (IKA,
Staufen, Germany) tissue grinder in PBS buffer containing 0.5% Nonidet P-40
and 0.5% deoxycholate. The homogenates were centrifuged in an Eppendorf
centrifuge for 10 min at 2,000 rpm. The obtained supernatant was recovered, and
the protein concentration was determined by the bicinchoninic acid assay
(Pierce). The homogenates were subjected to nonreducing sodium dodecyl sul-
fate–11% polyacrylamide gel electrophoresis, and the separated proteins were
transferred to an Immobilon-P nylon membrane (Millipore). CD46 was detected
with a rabbit antiserum (4).
For CAT assays 800 mg of protein from each tissue was processed according to
the supplier’s protocol (Promega). Briefly, the same volume of the reaction
mixture containing [14C]chloramphenicol (10 mCi; Du Pont), acetyl coenzyme A
(0.07 mg; Sigma), and 250 mM Tris HCl (pH 7.5) was used per reaction, and the
reaction mixture was incubated for 90 min at 37°C. Acetylated and nonacetylated
forms of chloramphenicol were separated on thin-layer silica gels (Sigma) and
visualized by autoradiography.
Mouse peripheral blood mononuclear cells (PBMC) were isolated from blood
samples by a density separation medium (Lympholyte-M; Cedarlane Laborato-
ries Ltd., Hornby, Ontario, Canada) according to the supplier’s protocol.
For histopathology animals were sacrificed and the brains were removed and
fixed by immersion in 4% PBS-buffered formaldehyde for 24 h at room temper-
ature. The tissues were embedded in paraffin and processed by standard tech-
niques. Sagittal and coronal sections were cut at 2 mm and stained with hema-
toxylin-eosin (HE). Lung tissues were processed in the same way. Glial fibrillary
acidic protein (GFAP) immunostaining for the detection of immunoreactive
astrocytes was performed with rabbit anti-GFAP polyclonal antibodies (Calbio-
chem) and biotinylated swine anti-rabbit antibodies. Antibody detection was
done with avidin-biotin-peroxidase (Vectastain Elite ABC and DAB-substrate
kits; Vector Labs, Burlingame, Calif.).
RESULTS
Transgenic mice expressing human CD46 with human-like
tissue specificity. CD46, a human cell surface protein for which
no murine homolog is available, is produced ubiquitously as
four major isoforms and protects host cells from complement
activation (31). These isoforms arise by alternative splicing and
differ in the presence or absence of a short, heavily O-glyco-
sylated domain (named B) and in having one of two cytoplas-
mic tails (named 1 and 2). To allow transfer to mice of the
whole human CD46 gene, including the unmapped locus con-
trol region(s), we selected a large YAC covering part of the
regulator of complement activation locus on human chromo-
some 1. In this YAC the 50-kb CD46 gene is preceded by the
CR1-like and the MCP-like genetic elements (18). After mi-
croinjection of purified YAC DNA into mouse oocytes, two
transgenic animals were obtained, of which one transmitted
the human CD46 gene; its progeny are referred to as CD46Ge.
The presence of the CD46 gene in litters was monitored by
PCR, and homozygous mice were subsequently identified by
FIG. 1. Genome analysis (A) and protein expression (B) of CD46Ge transgenic mice. (A) Genomic analysis of transgenic and control mice. Tail DNAs were
digested with EcoRI, separated on an agarose gel, blotted onto a nylon membrane, and hybridized with two probes, one recognizing two fragments (0.95 and 7.5 kb)
in the human CD46 promoter region and one recognizing a 2-kb fragment of the endogenous mouse Prn-p gene. Lane 2n, CD46 homozygous mouse; lane 1n, CD46
hemizygous mouse; lane 0n, control mouse. (B) CD46 protein expression in four organs obtained at autopsies of three humans (h1, h2, and h3) compared to the same
organs from a CD46 homozygous mouse (2n), a CD46 hemizygous mouse (1n), and a control mouse (0n). Thirty micrograms of protein from human tissue homogenates
or 15 mg of protein from mouse tissue homogenates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a nylon membrane,
and reacted against a polyclonal rabbit anti-CD46 serum. The molecular masses of marker proteins are indicated on the left in kilodaltons. The approximate positions
of the two major isoforms of the CD46 proteins (termed BC and C) are indicated on the right. CD46 proteins produced in different organs have different molecular
masses due to differential splicing and heterogeneous N- and O-glycosylation. Note that in humans different patterns of CD46 expression have been recognized (19).
Individuals h1 and h2 expressed approximately equivalent amounts of BC and C isoforms, whereas individual h3 may have had predominantly BC expression. CD46Ge
mice express equivalent amounts of the BC and C isoforms. The low quantity of protein detected in certain human autopsy samples, e.g., the brain of h1, may be because
of partial protein degradation.
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Southern blotting. Figure 1A presents an analysis of the ge-
nomes of two transgenic mice and one control animal. Two
probes, one recognizing two EcoRI fragments (0.95 and 7.5 kb)
in the CD46 promoter and one homologous to a 2-kb fragment
of an endogenous mouse gene (Prn-p; internal standard), were
used. The CD46 signals from the homozygous animal (2n)
were approximately twice as intense as those of the hemizygous
animal (1n), whereas no signal was detected in the control
animal (0n).
The ability of the chromosome 1 fragment to confer human-
like tissue-specific expression was tested by analyzing the pro-
teins produced in the kidney, lung, spleen, and brain. Protein
extracts from human autopsy material (Fig. 1B; individuals h1,
h2, and h3) were compared to extracts from CD46 homozy-
gous, hemizygous, and negative control mice. In these and all
other tissues examined and in concert with prior analyses,
CD46 isoforms were visualized as broad bands, most probably
due to differential splicing and to different levels of N- and
O-glycosylation (31). The electrophoretic mobilities and the
isoform patterns were similar in all matched tissues of mice
and humans, including brain tissue, where only fast-migrating
CD46 isoforms are produced (2, 19). Homozygous CD46 mice
expressed more CD46 than hemizygous animals.
We also measured CD46 expression on blood cells by flow
cytometry. Lymphocytes of transgenic mice (mean fluores-
cence, 12) reached levels comparable to those of human lym-
phocytes (mean fluorescence, 20), whereas mouse and human
erythrocytes did not express CD46 (mean fluorescence, 0.3).
Taken together, these results indicate that elements necessary
for expression of the human CD46 gene were transferred to
mice and suggest that differential splicing of human CD46
transcripts was faithfully reproduced in mice.
Respiratory MV infection of mice and its pathogenic con-
sequences. To compare the sensitivity to MV infection of
CD46-expressing animals and that of alpha/beta interferon-
defective animals, we inoculated these genetically modified
mice intranasally with the attenuated strain MV-Edm. The
mice were sacrificed 2 to 11 days postinfection (p.i.), and the
lungs were removed for RNA extraction. At autopsy, macro-
scopic purple lesion areas were noticed in Ifnartm mouse lungs
but not in CD46Ge mouse lungs. RT-PCR analysis of MV N
plus-strand RNA consistently revealed considerably stronger
signals in Ifnartm than in CD46Ge mice. Mock-infected mice
were consistently negative (not shown).
To obtain double-mutant mice, possibly more sensitive to
MV infection, the two lines were crossed. Intranasal challenge
was repeated with the resulting Ifnartm-CD46Ge animals, ho-
mozygous for both mutations, and with Ifnartm mice by using
200,000 infectious units of MV-Edm or of a modified MV-Edm
with an additional transcription unit expressing the reporter
protein CAT (MV-P-CAT). These two viruses were tran-
scribed at similar levels in the lungs (not shown). At autopsy,
purple lesion areas in the lung tissue of infected Ifnartm-
CD46Ge mice were larger than lesions in Ifnartm mice.
FIG. 2. Northern blot analysis of MV RNA in lungs of Ifnartm and Ifnartm-
CD46Ge mice intranasally inoculated with MV-P-CAT. Mice were sacrificed at
the days p.i. indicated. Five micrograms of total lung RNA was separated on a
1% formaldehyde-agarose gel, blotted to a nylon membrane, and reacted with an
antisense MV N RNA probe (top panel). The blot was stripped and rehybridized
with an actin RNA probe (bottom panel). As a positive control, 6 ng of total
RNA from MV-infected Vero cells was used (first lane) and, as a negative
control, 10 mg of total RNA from mock-infected Vero cells (second lane) was
used. As additional negative controls, total RNAs from two mock-infected mice
(2) were examined. A synthetic MV N plus-strand standard RNA 851 bases in
length (st 851) was added to the positive control. The positions of this standard
RNA, the N mRNA (about 1.7 kb), and the actin mRNA are indicated on the
right. About 30,000 copies of MV N mRNA are produced in MV-infected
primate cells (first lane) (9). Considering that about 800 times less RNA from
Vero cells than RNA from mouse lungs was loaded, the signal in the positive
control corresponds to about 40 copies of N mRNA per cell, and the signals in
the mouse lung tissues correspond to a few N mRNA copies per average cell.
FIG. 3. Results of histological analysis (A and B) and MV RNA detection
(C) in lung sections of intranasally infected Ifnartm-CD46Ge mice. After mock
infection (A) or inoculation with MV-Edm (B and C), the mice were sacrificed.
(C) A 2-mm-thick lung section hybridized with a MV N mRNA-specific probe.
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Figure 2 shows an analysis of the N mRNA produced in the
lungs of Ifnartm and Ifnartm-CD46Ge mice sacrificed 2, 4, 6, or
10 days after MV-P-CAT infection and in two control mice
sacrificed 4 days after mock infection. In the four mice sacri-
ficed on days 6 and 10, a positive signal was scored. In one of
these (the Ifnartm-CD46Ge mouse sacrificed at day 6), the
signal was very strong. In this and other experiments, RNA
from 18 Ifnartm-CD46Ge and 18 Ifnartm MV-Edm- or MV-P-
CAT-infected mice sacrificed 2 to 10 days p.i. was analyzed by
Northern blotting. Of the Ifnartm-CD46Ge mice, five were
strongly positive, eight were positive, and five were negative.
Four of the five mice with high levels of transcription were
those sacrificed 6 days p.i. The five mice with no detectable
transcription were sacrificed at day 2 (two of four sacrificed) or
day 4 (three of five sacrificed). Of the Ifnartm mice, 8 were
positive (none of four sacrificed on day 2, two of five sacrificed
on day 4, three of four sacrificed on day 6, and three of five
sacrificed on day 10) and 10 were negative. We conclude that
MV transcription in the lungs of Ifnartm-CD46Ge mice was
more efficient than that in Ifnartm mice and peaked around day
6.
We then studied the pathogenic effects of MV-Edm repli-
cation in the lungs. Histological examination of an Ifnartm-
CD46Ge animal sacrificed 6 days after infection revealed acute
lung inflammation, extensive hyperemia, and diffuse hemor-
rhage in large areas of the lungs (Fig. 3B). In contrast, in the
lung of a mock-infected animal (Fig. 3A) the alveolar lace-like
structure was generally preserved and only minor hemorrhage
was noticed.
To gain insight into the localization of MV-replicating cells
in the lung, we analyzed MV RNA expression in situ. Figure
3C demonstrates a section of an MV-infected Ifnartm-CD46Ge
mouse lung. Single cells and small groups of cells stained for
MV N mRNA. Due to the increased cellularity and the dis-
ruption of the normal lung architecture, the specificity of cells
replicating MV was difficult to determine, but groups of cells
were often located near the bronchial epithelium; on the other
hand, certain isolated cells were tentatively identified as mac-
rophages. No MV transcription was detected, as expected, in
mock-infected animals (not shown). This analysis indicates
that MV is transcribed in epithelial cells and possibly in mac-
rophages but overall in a small fraction of lung cells. Never-
theless, MV infection has striking pathological consequences.
Limited MV systemic propagation. To investigate if primary
MV replication in the lung was followed by systemic spread, we
took advantage of the reporter gene in MV-P-CAT. A CAT
assay of tissues from the same Ifnartm-CD46Ge animals uti-
lized for RNA analysis is presented in Fig. 4. Lungs were
collected from the animals sacrificed at days 2, 4, 6, and 10, and
livers, spleens, and kidneys were harvested from mice sacri-
ficed at days 6, 10, and 12. The CAT assay indicated a peak of
expression in the lungs at day 6. The other organ with CAT
activity at day 6 was the liver, which also tested weakly positive
in the animal sacrificed at day 10 and strongly positive in the
two animals sacrificed at day 12. In the spleen and kidney, CAT
activity was detected only at day 12. Generally, the results of
these assays confirmed the RNA analysis, but, due to the
higher sensitivity, more positive samples were identified. In
repeated experiments, systemic spread was always confirmed in
Ifnartm-CD46Ge mice and, to a lesser extent, also in Ifnartm
mice. We also isolated PBMC of infected Ifnartm-CD46Ge
mice and found low-to-intermediate levels of CAT activity 4 to
12 days p.i. (not shown). This observation raises the possibility
that CAT signals detected in organs may derive from circulat-
ing PBMC. The fact that in the livers the levels of CAT activity
were much higher than those in PBMC is not consistent with
this hypothesis. We conclude that in these mutant mice MV
propagates initially in the lungs and then in other organs.
Other parameters of mouse infection with MV were also in-
vestigated. The specific antibody response in C57BL/6, CD46Ge,
Ifnartm, and Ifnartm-CD46Ge mice was monitored by Western
blotting. In the last group of animals the anti-N response was
strongest (a positive signal with a 1:80,000 serum dilution [not
shown]) and reached its peak 21 days p.i. Neutralizing antibod-
ies were detected in Ifnartm-CD46Ge (1:170; background of
1:30) and Ifnartm (1:60) mice but were at background level in
the other two mouse lines. When the wild-type strain Chica-
go-1 was used to infect Ifnartm-CD46Ge mice, a 1:300 titer of
neutralizing antibodies was monitored. Thus, neutralizing an-
tibodies are produced only in alpha/beta interferon-defective
animals; MV replication in CD46Ge mice may be too ineffi-
cient to elicit synthesis of neutralizing antibodies.
Intracerebral inoculation with attenuated MV is lethal. We
next tested the sensitivity of genetically modified animals to
intracerebral infection with a virus expected to be nonpatho-
genic in control mice. We inoculated 6- to 8-week-old Ifnartm-
FIG. 4. MV spread in different organs of Ifnartm-CD46Ge mice. Mice intranasally inoculated (1) or mock infected (2) with MV-P-CAT were sacrificed at the days
p.i. indicated and tissues were collected, homogenized, and tested for CAT activity. As a positive control, Vero cells infected with MV-P-CAT were used (first lane),
and as a negative control, mock-infected Vero cells (second lane) were used. The lung extract of a mouse sacrificed 4 days after mock infection is shown in the fifth
lane.
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CD46Ge, Ifnartm, CD46Ge, and control mice with high doses
(1 million infectious units) of MV-Edm (Fig. 5A). Sixteen of 18
infected Ifnartm-CD46Ge mice died, 2 on day 3, 8 on day 4, 2
each on days 5 and 6, and 1 each on days 7 and 9. Eight of 18
Ifnartm animals died between days 4 and 7. All of these animals
showed clinical signs of neural disease, including initial hyper-
activity which was followed by awkward gait, lethargy, lack of
mobility, and death. In control and CD46Ge mice, 1 of a total
of 24 animals died but did not develop signs of neurologic
illness. We conclude that MV-Edm is pathogenic in adult mice
only if their type I interferon response is defective.
The differential susceptibility of the Ifnartm-CD46Ge and
Ifnartm mice was more pronounced if less virus (105 infectious
units) was inoculated: 12 of 13 Ifnartm-CD46Ge mice but only
1 of 6 Ifnartm mice died (Fig. 5C). If 3,000 infectious units of
MV-Edm was inoculated exclusively in Ifnartm-CD46Ge mice,
seven of eight animals died between 5 and 27 days after infec-
tion. Thus, though the Ifnartm-CD46Ge mortality remained
nearly 90%, the incubation time was prolonged.
We then verified in Ifnartm-CD46Ge and Ifnartm animals the
pathogenic effects of a MV strain independent of the presence
of CD46 for cell entry. Since Ifnartm-CD46Ge and Ifnartm mice
are not isogenic, they could have different susceptibilities to
MV infection independent of the availability of the human
receptor. After inoculation of 104 infectious units of the rodent
brain-adapted neurotropic MV strain CAM/RBH, we ob-
served that one of eight control animals and two of eight
CD46Ge animals died 11 to 18 days p.i. (Fig. 5B). In contrast,
one-half of the Ifnartm and Ifnartm-CD46Ge animals suc-
cumbed 5 to 11 days p.i. (Fig. 5B). These results indicate that
the different genetic backgrounds of the Ifnartm and Ifnartm-
CD46Ge mice do not measurably influence MV pathogenesis,
a result which was not unexpected because their H-2 haplo-
types are equivalent in terms of sensitivity to MV-induced
encephalitis (38).
Pathogenic consequences of MV replication in the brain. To
determine the cell specificity of MV replication and to gain
insight into the nature of MV-induced disease, the brains of
Ifnartm-CD46Ge mice were examined 3 days after intracere-
bral inoculation. An HE-stained sagittal section of a mock-
infected brain is shown in Fig. 6A: the meninges are thin and
the parenchyma is intact. The corresponding section of a MV-
Edm-infected brain (Fig. 6B) disclosed meningitis with inflam-
matory infiltrates of leukocytes and extensive vacuolization
and necrosis of nearby brain parenchyma. Staining for GFAP
revealed numerous reactive astrocytes in many brain areas. In
Fig. 6C astrocytes were detected around, but not within, a
region of extensive cell necrosis. An HE staining of the central
area of the same region is shown at higher magnification in Fig.
6D; strong vacuolization is evident. Marked necrosis of neu-
rons was also observed in the cerebral cortex, corpus callosum,
and hypothalamus (not shown). In the brains of Ifnartm mice,
less extensive pathogenic signs and no necrosis were observed,
whereas in the brains of nonmutant control mice local, limited
meningitis was occasionally monitored. In summary, MV-Edm-
infected brains of Ifnartm-CD46Ge and, to a lesser extent, of
Ifnartm mice (not shown) are characterized by severe general-
ized meningitis, multifocal gliosis, and marked necrosis of neu-
rons as early as 3 days after infection. All of these pathological
changes have a bilateral distribution.
Next the replication of MV in infected brains was monitored
by in situ hybridization with a MV N mRNA-specific probe
(Fig. 6E and F) and by N protein immunohistochemistry (not
shown). Microscopic examination of tissue sections indicated
that ependymal cells lining the ventricles stained strongly, to-
gether with scattered neurons and oligodendrocytes (Fig. 6E).
The inset in (Fig. 6E) shows a hippocampal neuron in which
not only the cell body but also an extension, directed towards
infected glial cells, is positive for MV N mRNA. At higher
magnification the regions lining the ventricles revealed groups
of positive cells (Fig. 6F). Occasionally, infected cells were also
detected in the meninges (not shown). We interpret the dis-
tribution of infected cells in the brain to indicate that the
propagation of MV infection was largely on the basis of cell-
cell contact.
DISCUSSION
We show here that MV spread and pathogenesis in mice are
controlled by alpha/beta interferon. Even in the absence of a
high-affinity receptor for virus attachment, intranasal inocula-
tion of Ifnartm mice results in moderate MV propagation. The
availability of the high-affinity receptor CD46 facilitates MV-
Edm spread and exacerbates its pathogenic consequences.
FIG. 5. Survival of mice from four strains after intracerebral inoculation with
the vaccine strain MV-Edm (A and C) or with the neurotropic strain CAM/RBH
(B). (A and B) Six- to 8-week-old mice were injected intracerebrally with 1
million infectious units of MV-Edm or with 104 infectious units of the rodent
brain-adapted neurotropic CAM/RBH strain. Open circles, Ifnartm-CD46Ge
mice; dots, Ifnartm mice; open triangles, CD46Ge mice; filled triangles, con-
trol C57BL/6 mice. The numbers of animals injected were as follows: (A) 18
Ifnartm-CD46Ge and Ifnartm and 12 CD46Ge and C57BL/6 mice; (B) 8 from
each mouse strain. (C) Susceptibilities of Ifnartm and Ifnartm-CD46Ge mice to
different doses of MV-Edm. Columns: A, numbers of inoculated/dead mice; B,
average day of death. nd, not determined.
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CD46 expression in humans and CD46Ge mice. CD46 is
expressed on almost all human nucleated cells in one of three
patterns: predominantly the BC isoform (65% of the popula-
tion), approximately equal quantities of B and C (29%), and
predominantly the C isoform (6%) (31). However, in the brain
the C isoform is preferentially expressed, independent of which
of the three patterns is present in other tissues (19). Also, there
is roughly equal expression of protein isoforms with cytoplas-
mic tail 1 or 2 in all tissues but the brain, where the tail-2
isoform is preferentially, if not exclusively, expressed (2, 19,
31). This pattern of isoform expression was duplicated in the
transgenic mice (Fig. 1B), including that of the C isoform
bearing cytoplasmic tail 2 being highly expressed in brain tissue
(data not shown). Thus, the trans-acting regulatory elements
necessary to reproduce human-like tissue specificity with the
human CD46 gene are functional in all mouse tissues exam-
ined, including brain tissue. This transgenic mouse system can
now be utilized to assess the regulation of this remarkable
example of tissue-specific expression.
Additionally, since the pathogenic bacteria Streptococcus
FIG. 6. Histological analysis of the consequences of MV infection and of the MV RNA distribution in the brains of Ifnartm-CD46Ge animals. A mouse inoculated
with 1 million infectious units of MV-Edm (B to F) and a mock-infected mouse (A) were sacrificed 3 days p.i., their brains were prepared, and brain slices were stained
as indicated below. (A, B, and D) HE-stained sections showing meningeal inflammation (B) and necrosis (B and D) of the brain tissue. (C) Immunohistochemical
staining for GFAP demonstrating reactive astrocytes (brown) surrounding necrotic lesions. (E and F) In situ hybridization with a MV N-specific probe showing strong
staining in the ventricular region and in scattered neurons. One infected hippocampal neuron is enlarged in the inset. In panel F, many contiguous ependymal cells
are stained.
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pyogenes, Neisseria gonorrhoeae, and Neisseria meningitidis use
CD46 as their receptor (21, 41), CD46 mice are becoming a
new tool in animal studies of bacterial cell adhesion and patho-
genesis (20).
Respiratory tract MV infection of mice. MV RNA was detect-
ed in the lungs of CD46Ge mice only by reverse transcription-
PCR, but MV infection in the lungs of Ifnartm and Ifnartm-
CD46Ge mice was unequivocal. Northern blots and MV
replication-dependent CAT expression confirmed the in situ
hybridization analysis, ruling out the possibility of detection of
contaminating inoculum. Histological analysis of Ifnartm-
CD46Ge mouse lungs revealed pathogenic changes compara-
ble to those observed in intranasally infected macaques (1, 32).
Neutralizing antibodies were detected.
However, infectious virus was recovered only occasionally at
days 2 to 4 p.i. from lung or brain tissues and never from other
organs (not shown). Virus isolation was achieved by cocultiva-
tion of mouse lung cell homogenates with indicator cells, but it
was not possible to recover released virus (not shown). These
data suggest that in mice a late stage of virus replication,
possibly assembly or release, is inefficient. Indeed it was pre-
viously noticed that the MV titers obtained in CD46-expressing
rodent cells are considerably lower than those obtained in
primate cells (4, 36) and that cells of CD46 transgenic mice
have different permissivities to MV infection (17).
Even in the virtual absence of detectable virus release the
MV infection propagated to the three other tissues examined,
spleen, liver, and kidney. Replication was highest in liver tis-
sue, consistent with the occurrence of postmeasles hepatitis in
humans (24). Since MV propagation in humans may be based
on infection of lymphocytes and macrophages (40), we isolated
PBMC from Ifnartm-CD46Ge and indeed found evidence for
MV replication. We conclude that in interferon-defective mice
MV may propagate largely in a cell-associated manner, initially
in lung macrophages and then in a subset of PBMC.
Efficiency of cell entry and pathogenesis. In mouse MV
infections the efficiency of cell entry is not the principal deter-
minant of pathogenesis. In this respect MV is different from
poliovirus, because transgenic mice expressing the poliovirus
receptor become highly susceptible to infection and die of po-
liomyelitis (25, 47).
Nevertheless, efficiency of MV cell entry and pathogenesis
are linked: neurotropic MV strains selected by virus adaptation
to rodent brain cells accumulate alterations in the MV attach-
ment protein H (30). We confirmed the causality of this link by
challenging Ifnartm and Ifnartm-CD46Ge mice either with a
MV strain dependent on CD46 for cell entry (MV-Edm) or a
rodent brain-adapted strain (CAM/RBH). The pathogenic ef-
fects of MV-Edm were more pronounced in Ifnartm-CD46Ge
than in Ifnartm mice, whereas CAM/RBH was equally patho-
genic in both transgenic strains. This proves that more efficient
cell entry can cause enhanced pathogenesis.
In this context it is important to understand that the MV-
CD46 interaction has several consequences: not only does it
allow efficient virus entry, but it may also cause complement-
mediated cell lysis via CD46 downregulation (53), and it may
be one of the causes of suppression of cell-mediated immunity
(14, 22, 37, 49). In view of these different effects, the interac-
tions between CD46 and the H proteins of different MV strains
are being characterized in detail (3, 27, 51).
MV infection of mouse brains. MV replication is much more
efficient in the rodent central nervous system than in the pe-
riphery (29). Nevertheless, brain MV spread and pathogenicity
decrease with age of the mouse and are limited to certain MV
strains (16). Accordingly, concentrated inocula of the attenu-
ated strain MV-Edm failed to cause disease in adult control or
CD46Ge animals. The same inocula were lethal within a few
days for half of the Ifnartm mice and for almost all Ifnartm-
CD46Ge animals. The extremely fast disease course in these
animals (3 to 9 days), with virus propagating mostly in the
easily accessible ependymal cells, implies a fundamental dif-
ference from other MV-induced brain diseases.
Less concentrated inocula (3,000 infectious units per ani-
mal) remained lethal for Ifnartm-CD46Ge mice, but the ani-
mals survived for up to 4 weeks. The recent examination of
the brains of such animals at different times after infection
(7) revealed progressive MV infection of neural cells, as ob-
served in the brains of neonatally infected mice expressing a
single CD46 isoform under the control of a neuron-specific
promoter (NSE-CD46) (46). It is important to note another
constant in the infections of neonatal NSE-CD46 mice and of
adult Ifnartm-CD46Ge mice: virus RNA or antigen was often
detected in contiguous cells, suggesting that in the brain MV
propagation may be based largely on lateral cell-cell contacts.
Perspectives. Mice with a defective interferon system may
not be a general model for MV-induced disease, but Ifnartm-
CD46Ge animals are being used for specific purposes: first, to
compare the spread of standard MV and of reconstituted vi-
ruses with alterations of the envelope proteins characteristic of
SSPE (7, 8, 10) in the brain; second, to address the important
issue of the receptor specificities of wild-type MV strains (51)
by comparing their pathogenicities in Ifnartm-CD46Ge and
Ifnartm mice; and third, to test recently produced MV mutants
(44, 50) in which proteins possibly required for pathogenesis
(23) are inactivated. It will be instructive to compare the results
of pathogenesis tests performed in Ifnartm-CD46Ge mice and
rhesus macaques.
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